Neurocrine is beefing up its pipeline, splurging $50M on rights to an epilepsy drug
Neurocrine has stepped up with $50 million in cash and a bundle of biobucks to bag rights to an early-stage epilepsy drug out of Xenon …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
